Form 4: Entero Therapeutics CFO Sells Shares to Cover Tax Obligations

Sarah Romano, CFO of Entero Therapeutics, sold 727 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

• On January 6, 2025, Sarah Romano, the Chief Financial Officer of Entero Therapeutics, Inc. (ENTO), sold 727 shares of common stock.
• The shares were sold at a price of $0.64 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• Following the transaction, Romano directly owns 17,287 shares of Entero Therapeutics, Inc., including unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations, not necessarily reflecting a change in the executive's confidence in the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial condition.

Key Dates

Keywords

Form 4, Entero Therapeutics, Sarah Romano, CFO, Stock Sale, RSU, Tax Withholding